HUP0300857A3 - Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists - Google Patents

Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Info

Publication number
HUP0300857A3
HUP0300857A3 HU0300857A HUP0300857A HUP0300857A3 HU P0300857 A3 HUP0300857 A3 HU P0300857A3 HU 0300857 A HU0300857 A HU 0300857A HU P0300857 A HUP0300857 A HU P0300857A HU P0300857 A3 HUP0300857 A3 HU P0300857A3
Authority
HU
Hungary
Prior art keywords
oxazolyl
acid derivatives
ppar agonists
arylpropionic acid
arylpropionic
Prior art date
Application number
HU0300857A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUP0300857A2 publication Critical patent/HUP0300857A2/hu
Publication of HUP0300857A3 publication Critical patent/HUP0300857A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
HU0300857A 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists HUP0300857A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22723400P 2000-08-23 2000-08-23
PCT/US2001/022616 WO2002016331A1 (en) 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Publications (2)

Publication Number Publication Date
HUP0300857A2 HUP0300857A2 (hu) 2003-10-28
HUP0300857A3 true HUP0300857A3 (en) 2007-03-28

Family

ID=22852309

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300857A HUP0300857A3 (en) 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Country Status (26)

Country Link
US (2) US6930120B2 (enExample)
EP (1) EP1313716B1 (enExample)
JP (1) JP2004506721A (enExample)
KR (1) KR20030027054A (enExample)
CN (1) CN1471517A (enExample)
AT (1) ATE361283T1 (enExample)
AU (1) AU2001284659A1 (enExample)
BR (1) BR0113409A (enExample)
CA (1) CA2418104A1 (enExample)
CY (1) CY1107679T1 (enExample)
CZ (1) CZ2003482A3 (enExample)
DE (1) DE60128239T2 (enExample)
DK (1) DK1313716T3 (enExample)
EA (1) EA200300286A1 (enExample)
EC (1) ECSP034504A (enExample)
ES (1) ES2286137T3 (enExample)
HU (1) HUP0300857A3 (enExample)
IL (1) IL154110A0 (enExample)
MX (1) MXPA03001558A (enExample)
NO (1) NO20030729L (enExample)
NZ (1) NZ523804A (enExample)
PL (1) PL360744A1 (enExample)
PT (1) PT1313716E (enExample)
SK (1) SK1872003A3 (enExample)
WO (1) WO2002016331A1 (enExample)
ZA (1) ZA200300570B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2420178A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
CA2418134A1 (en) 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
RU2278859C2 (ru) * 2001-05-15 2006-06-27 Ф.Хоффманн-Ля Рош Аг Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета
KR100459917B1 (ko) * 2001-12-14 2004-12-03 (주)바이오뉴트리젠 페놀릭산 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
PL374818A1 (en) 2002-07-03 2005-10-31 F.Hoffmann-La Roche Ag Oxazole derivatives and their use as insulin sensitizers
ATE483699T1 (de) * 2002-08-30 2010-10-15 Hoffmann La Roche Neue 2-arylthiazolverbindungen als ppar-alpha und gamma agonisten
WO2004024726A1 (en) 2002-09-12 2004-03-25 F. Hoffmann-La Roche Ag N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
CA2503117C (en) 2002-11-08 2010-12-21 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as ppar agonists
DE60323130D1 (de) 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
ES2286679T3 (es) * 2003-08-20 2007-12-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para la liberacion oral de un compuesto de peptido de tipo glucagon (glp)-1 o un peptido agonist a del receptor de melanocortina 4 (mc4).
EP1658273B1 (en) * 2003-08-20 2007-01-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
WO2005100318A1 (en) * 2004-04-14 2005-10-27 Ranbaxy Laboratories Limited Alkanoic acids and their esters as antidiabetic agents
JPWO2006057448A1 (ja) * 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US6062509A (en) 1994-12-23 2000-05-16 Hexcel Corporation Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports
JP2002503202A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
RU2174121C2 (ru) * 1996-08-19 2001-09-27 Джапан Тобакко Инк. Производные пропионовой кислоты и фармацевтическая композиция на их основе
DE69941777D1 (de) 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
WO2001016120A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
CA2418134A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
CA2420178A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Also Published As

Publication number Publication date
ECSP034504A (es) 2003-04-25
PL360744A1 (en) 2004-09-20
DE60128239D1 (de) 2007-06-14
ES2286137T3 (es) 2007-12-01
AU2001284659A1 (en) 2002-03-04
NO20030729L (no) 2003-04-02
NZ523804A (en) 2004-09-24
EP1313716A1 (en) 2003-05-28
BR0113409A (pt) 2003-07-01
EP1313716B1 (en) 2007-05-02
US20050245584A1 (en) 2005-11-03
WO2002016331A1 (en) 2002-02-28
JP2004506721A (ja) 2004-03-04
MXPA03001558A (es) 2003-06-06
CN1471517A (zh) 2004-01-28
CZ2003482A3 (cs) 2003-05-14
HUP0300857A2 (hu) 2003-10-28
CY1107679T1 (el) 2013-04-18
DK1313716T3 (da) 2007-08-27
NO20030729D0 (no) 2003-02-14
PT1313716E (pt) 2007-07-11
ZA200300570B (en) 2004-04-21
US6930120B2 (en) 2005-08-16
IL154110A0 (en) 2003-07-31
US7345070B2 (en) 2008-03-18
US20040097590A1 (en) 2004-05-20
DE60128239T2 (de) 2008-01-10
EA200300286A1 (ru) 2003-08-28
SK1872003A3 (en) 2003-07-01
ATE361283T1 (de) 2007-05-15
CA2418104A1 (en) 2002-02-28
KR20030027054A (ko) 2003-04-03

Similar Documents

Publication Publication Date Title
IL147821A0 (en) Benzoic acid derivatives and their use as ppar receptor agonists
HUP0201633A2 (en) Alpha-aminosulphonyl-acetohydroxamic acid derivatives with metalloprotease inhibiting effect, preparation and use thereof
PL362917A1 (en) New mandelic acid derivatives and their use as throbin inhibitors
IL154031A0 (en) Substituted sulfonylaminomethylbenzoic acid derivatives and preparation
IL154604A0 (en) Guanidinobenzamides as mc4-r agonists
SI1371647T1 (en) Pyridine-3-carboxylic acid derivatives and their use as intermediates
IL155634A0 (en) 3-arylindole derivatives and their use as cb2 receptor agonists
IL149374A0 (en) New use and novel n-azabicyclo-amide derivatives
IL149361A0 (en) Picolinic acid derivatives and their use as fungicides
IL151614A0 (en) Apomorphine derivatives and methods for their use
HUP0203961A3 (en) 3-phenoxy-1-phenyl acetylene derivatives and their use as herbicedes
ZA200410054B (en) Propionic acid derivatives and their use as hPPARsactivators.
SI1551814T1 (sl) Derivati kiralne oksazol-arilpropionske kisline in njihova uporaba kot ppar-agonisti
HUP0302306A3 (en) Propionic acid derivatives with ppar-alpha activating properties
AU2001235437A1 (en) Isothiazolecarboxylic acid derivatives and their use as microbicides
IL158056A0 (en) Chemical derivatives and their use as anti-telomerase agent
AU2001291744A1 (en) Arylpiperazine derivatives and their use as psychotropic agents
PL359668A1 (en) Biphenyl derivatives and the use thereof as integrin inhibitors
SI1259515T1 (en) Thienopyridine derivatives and their use as anti-inflammatory agents
AU2001282268A1 (en) Phenantridine derivatives and their use as anti-telomerase agent
PL355845A1 (en) Substituted isoquinoline derivatives and their use as inticonvulsants
HK1057041A (en) Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
IL156794A0 (en) Chemical derivatives and their use as anti-telomerase agent
AU8973201A (en) Biphenyl derivatives and the use thereof as integrin inhibitors
HRP20020971A2 (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-inhibitors

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees